Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 192,228
  • Shares Outstanding, K 13,405
  • Annual Sales, $ 13,110 K
  • Annual Income, $ -124,020 K
  • EBIT $ -126 M
  • EBITDA $ -124 M
  • 60-Month Beta 1.75
  • Price/Sales 14.30
  • Price/Cash Flow N/A
  • Price/Book 0.73

Options Overview Details

View History
  • Implied Volatility 131.98% (+3.65%)
  • Historical Volatility 85.45%
  • IV Percentile 43%
  • IV Rank 38.89%
  • IV High 187.25% on 03/05/26
  • IV Low 96.80% on 01/21/26
  • Expected Move (DTE 24) 3.23 (23.91%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 474
  • Volume Avg (30-Day) 306
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 2,000
  • Open Int (30-Day) 3,458
  • Expected Range 10.28 to 16.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-2.38
  • Number of Estimates 3
  • High Estimate $-1.93
  • Low Estimate $-3.14
  • Prior Year $-2.84
  • Growth Rate Est. (year over year) +16.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.60 +16.44%
on 03/30/26
16.36 -17.42%
on 03/24/26
-1.49 (-9.93%)
since 03/20/26
3-Month
11.60 +16.44%
on 03/30/26
19.95 -32.28%
on 01/22/26
-4.66 (-25.65%)
since 01/21/26
52-Week
11.60 +16.44%
on 03/30/26
69.97 -80.69%
on 08/14/25
-1.45 (-9.69%)
since 04/21/25

Most Recent Stories

More News
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years TONMYA commercially...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic   Phase 1 study of TNX-4800 demonstrated safety, tolerability,...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Intranasal oxytocin blocks the release of calcitonin gene-related peptide ( CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and trigeminal...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease  Wednesday, April 1: Animal and in vitro studies...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company,...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company,...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain...

TNXP : 13.51 (-5.79%)
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults...

TNXP : 13.51 (-5.79%)

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 14.95
2nd Resistance Point 14.65
1st Resistance Point 14.08
Last Price 13.51
1st Support Level 13.21
2nd Support Level 12.91
3rd Support Level 12.34

See More

52-Week High 69.97
Fibonacci 61.8% 47.67
Fibonacci 50% 40.79
Fibonacci 38.2% 33.90
Last Price 13.51
52-Week Low 11.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.